(Total Views: 636)
Posted On: 02/06/2021 9:00:11 PM
Post# of 155256
Thanks for reposting, Techguru.
The "Hypothesis Letter" published November 2019 entitled "Blockade of CCR5 in melanoma: An alternative immune checkpoint modulator" suggests CCR5 blockade as a complement and/or replacement to Keytruda/Opdivo because of the Keytruda/Oodivo side effects combined with the known immunomodulatory effects of leronlimab.
It really seems quite remarkable to me that these authors are suggesting leronlimab as worthy of further study as a Keytruda/Oodivo complement/alternative while the authors make no mention of CCR5 blockade's suppressive effect on PDL1.
Surely if these authors were aware of the CCR5 bockade PDL1 suppression published only four months later in April 2020, these authors would have mentioned it.
My suspicion is that Bristol Meyers Squibb and others currently trialing CCR5 blockade in human cancer trials did not do so because of CCR5 blockade PDL1 suppression.
The "Hypothesis Letter" published November 2019 entitled "Blockade of CCR5 in melanoma: An alternative immune checkpoint modulator" suggests CCR5 blockade as a complement and/or replacement to Keytruda/Opdivo because of the Keytruda/Oodivo side effects combined with the known immunomodulatory effects of leronlimab.
It really seems quite remarkable to me that these authors are suggesting leronlimab as worthy of further study as a Keytruda/Oodivo complement/alternative while the authors make no mention of CCR5 blockade's suppressive effect on PDL1.
Surely if these authors were aware of the CCR5 bockade PDL1 suppression published only four months later in April 2020, these authors would have mentioned it.
My suspicion is that Bristol Meyers Squibb and others currently trialing CCR5 blockade in human cancer trials did not do so because of CCR5 blockade PDL1 suppression.
(2)
(0)
